2 Information about encorafenib with binimetinib

Marketing authorisation

2.1 Encorafenib (Braftovi, Pierre Fabre) in combination with binimetinib (Mektovi, Pierre Fabre) is indicated for 'the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation'.

Dosage in the marketing authorisation

2.2 For encorafenib, the recommended dose is 450 mg (6×75‑mg capsules) taken orally, once daily. For binimetinib, the recommended dose is 45 mg (3×15‑mg tablets) taken orally, twice daily, 12 hours apart.


2.3 The list price for 42 capsules of encorafenib 75 mg is £1,400 and for 84 tablets of binimetinib 15 mg is £2,240 (company submission). The company has a commercial arrangement for each drug. This makes encorafenib with binimetinib available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.

  • National Institute for Health and Care Excellence (NICE)